The invention belongs to the technical field of probiotics, and particularly relates to
bifidobacterium animalis XY01 with an
inflammation relieving effect and application of the
bifidobacterium animalis XY01. A novel
Bifidobacterium animalis XY01 strain is separated from faeces of a healthy infant in Guangzhou city, Guangdong province, and research finds that the strain can inhibit aggregation of in-vivo macrophages at an
inflammation part, promote subtraction of the macrophages from the
inflammation part, reduce expression of in-vivo IL-6, IL-1beta and TNF-alpha, reduce
hyaluronidase activity and inhibit inflammation of the infant. The
chitinase activity is improved, and the potential inflammation relieving effect is achieved. Therefore, the bacterium has huge potential in the aspects of treatment and prevention of inflammation-related diseases, can be used for developing novel anti-inflammatory drugs, can also be used as a functional component to be added into health-care products, is beneficial to relieving
inflammatory response and maintaining
human health, and provides a new way and method for improving inflammation-related
health problems.